On Thursday 22 July, pharmaceutical company Sanofi announced that they will be delisting Aubagio (teriflunomide) from the Australian market effective 1 October 2021.
Aubagio (teriflunomide) is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS).
People who hold prescriptions will still be able to access it until the Australian stock runs out, following that generic brands of teriflunomide will be available.
We recommend you contact your neurologist if this impacts you or you are concerned.
For more information, visit the MS Australia website.